The oncologist

publication venue for

Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines. 2021
Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases. 2017
Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer? 2012
Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers.. 29. 2024
Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy. 2024
TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations. 2024
Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer. 2024
Elements of End-of-Life Discussions Associated With Patients' Reported Outcomes and Actual End-of-Life Care in Patients With Pretreated Lung Cancer.. 29. 2024
Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial. 2023
The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review. 2023
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial. 2023
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer. 2023
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399. 2023
Exocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors. 2023
Specialty Differences in Medical Aid in Dying Experiences: Results of a Survey of Physicians in Colorado. 2023
Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.. 28. 2023
Associations Between Race/Ethnicity, Language, and Enrollment on Cancer Research Studies.. 28. 2023
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy. 2023
Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data. 2022
Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network.. 27. 2022
Prognostic Awareness and Discussions of Incurability in Patients with Pretreated Non-Small Cell Lung Cancer and Caregivers: A Prospective Cohort Study.. 27. 2022
Physician Payments from Pharmaceutical Companies Related to Cancer Drugs.. 27. 2022
Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma.. 27. 2022
Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer.. 27. 2022
Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status.. 27. 2022
Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil. 2022
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. 2022
Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.. 26. 2021
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.. 26. 2021
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. 2021
Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. 2021
Prescription Opioids Dispensed to Patients with Cancer with Bone Metastasis: 2011-2017. 2021
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.. 26. 2021
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3.. 26. 2021
Opportunities for Improvement in the Administration of Neoadjuvant Chemotherapy for T4 Breast Cancer: A Comparison of the U.S. and Nigeria.. 26. 2021
Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines.. 26. 2021
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.. 26. 2021
Antibiotics and Imiquimod for Cutaneous T-Cell Lymphoma in Veterans: A Patient Population with Agent Orange Exposure.. 26. 2021
Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19.. 26. 2021
Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors.. 26. 2021
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up.. 26. 2021
Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.. 26. 2020
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.. 25. 2020
Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).. 25. 2020
ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling.. 25. 2020
Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.. 25. 2020
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.. 25. 2020
A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.. 25. 2020
Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (¹⁷⁷ Lu-J591) for Metastatic Castration-Resistant Prostate Cancer.. 25. 2020
Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study.. 25. 2019
Extended Survival After Surgical Resection for Pituitary Metastases: Clinical Features, Management, and Outcomes of Metastatic Disease to the Sella.. 25. 2019
A Multidisciplinary Head-to-Head Comparison of American College of Radiology Thyroid Imaging and Reporting Data System and American Thyroid Association Ultrasound Risk Stratification Systems.. 25. 2019
Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer.. 25. 2019
Improving Cancer Diagnosis and Care: Patient Access to High-Quality Oncologic Pathology.. 24. 2019
A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor.. 24. 2019
Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.. 24. 2019
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer.. 24. 2019
Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.. 24. 2019
Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.. 24. 2019
A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.. 24. 2018
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.. 24. 2018
A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors.. 24. 2018
Development and Validation of a Clinical Score for Cardiovascular Risk Stratification of Long-Term Childhood Cancer Survivors.. 23. 2018
Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.. 23. 2018
Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy.. 23. 2017
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.. 23. 2017
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results.. 22. 2017
Cancer Immunotherapy Trials Underutilize Immune Response Monitoring.. 23. 2017
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.. 23. 2017
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.. 22. 2017
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.. 22. 2017
Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.. 22. 2017
Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.. 22. 2017
Complete Metabolic Response on Interim ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.. 22. 2017
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.. 22. 2017
Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer Patients with Acute Myocardial Infarction.. 22. 2017
A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.. 22. 2016
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.. 22. 2016
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.. 21. 2016
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.. 21. 2016
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).. 21. 2016
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.. 21. 2016
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.. 21. 2016
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.. 21. 2016
Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.. 21. 2016
Sentinel Lymph Node Mapping in Endometrial Cancer: An Update.. 21. 2016
Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy.. 21. 2016
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.. 20. 2015
Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute.. 20. 2015
Prognostic Importance of Pretransplant Functional Capacity After Allogeneic Hematopoietic Cell Transplantation.. 20. 2015
Ramucirumab for Colon Cancer and the Problem of Rising Prices Independent of Benefits.. 20. 2015
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes.. 20. 2015
Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.. 20. 2015
Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer.. 20. 2015
Posterior Reversible Encephalopathy Syndrome in Patients With Cancer.. 20. 2015
Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women.. 20. 2015
Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review.. 20. 2015
A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.. 20. 2015
Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer.. 20. 2015
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.. 20. 2015
Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma.. 20. 2015
Chronic thalidomide and chemoembolization for hepatocellular carcinoma.. 19. 2014
Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.. 19. 2014
Pre-exercise participation cardiovascular screening in a heterogeneous cohort of adult cancer patients.. 19. 2014
A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer.. 19. 2014
Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer.. 18. 2013
Ipilimumab for patients with advanced mucosal melanoma.. 18. 2013
The NOMS framework: approach to the treatment of spinal metastatic tumors.. 18. 2013
Toxicity of bevacizumab in combination with chemotherapy in older patients.. 18. 2013
Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.. 18. 2013
Breast cancer genomics: challenges in interpretation and application.. 18. 2013
Doublet chemotherapy in the elderly patient with ovarian cancer.. 17. 2012
Truth-telling and cancer diagnoses: physician attitudes and practices in Qatar.. 17. 2012
A pilot randomized controlled trial of brief cognitive-behavioral therapy for anxiety in patients with terminal cancer.. 17. 2012
The effect of age on delay in diagnosis and stage of breast cancer.. 17. 2012
First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.. 17. 2012
Immunogenicity of an inactivated monovalent 2009 influenza A (H1N1) vaccine in patients who have cancer.. 17. 2012
Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer.. 16. 2011
Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy.. 16. 2011
An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.. 16. 2011
KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice.. 16. 2011
Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.. 16. 2011
Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.. 16. 2011
Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?. 16. 2011
Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.. 16. 2011
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).. 15. 2010
Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study.. 15. 2010
CXCR4 expression in early breast cancer and risk of distant recurrence.. 14. 2009
The chronology of distress, anxiety, and depression in older prostate cancer patients.. 14. 2009
A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer.. 14. 2009
Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.. 14. 2009
Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies.. 14. 2009
Effects of aerobic exercise training in anemic cancer patients receiving darbepoetin alfa: a randomized controlled trial.. 13. 2008
Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.. 13. 2008
Prognostic value of initial clinical disease stage after achieving pathological complete response.. 13. 2008
Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor--positive operable breast cancer.. 12. 2007
Trends for inflammatory breast cancer: is survival improving?. 12. 2007
Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.. 11. 2006
Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.. 11. 2006
A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.. 7. 2002
Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer.. 7. 2002
Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients.. 6. 2001
Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.. 5. 2000
Intensity modulated radiation therapy (IMRT): a new promising technology in radiation oncology.. 4. 1999
Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.. 4. 1999
Adjuvant Drug Treatment for Resectable Breast Cancer.. 2. 1997
Clinical Use of Irinotecan: Current Status and Future Considerations.. 2. 1997
Adjuvant Chemotherapy of Colorectal Cancer.. 1. 1996
Drug Resistance.. 1. 1996
Next-Generation Sequencing in the Diagnosis of Metastatic Lesions: Reclassification of a Glioblastoma as an Endometrial Cancer Metastasis to the Brain
Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience.. 24. 2019
In Reply.. 23. 2018
In reply.. 20. 2015
Randomization and statistical power: paramount in trial reproducibility (even for rare cancers). 2012
In reply. 2013
Squamous cell carcinoma of the oral tongue in two patients previously exposed to long-term pegylated liposomal doxorubicin. 2012
Untreated patients in "CT screening for lung cancer: update 2007". 2008
Response to "CT screening for lung cancer: update 2007". 2008
Breast cancer highlights: key findings from the San Antonio Breast Cancer Symposium: a U.S. perspective. 2004
Breaking down the evidence for bevacizumab in ovarian cancer.. 20. 2015
Micropapillary pattern in newly diagnosed borderline tumors of the ovary: what's in a name?. 16. 2011
The weaknesses of science for profit.. 7. 2002
Magnetic Resonance Imaging-Based Screening for Asymptomatic Brain Tumors: A Review. 2018
Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors. 2018
The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics. 2013
Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. 2011
Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics. 2010
Controversies in the treatment of lymphoma with autologous transplantation. 2009
Sentinel lymph node biopsy in the management of vulvar carcinoma, cervical cancer, and endometrial cancer. 2009
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. 2008
The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. 2008
Retinoblastoma: review of current management. 2007
Presurgical chemotherapy in patients being considered for liver resection. 2007
Role of minimally invasive surgery in gynecologic cancers. 2006
Locally advanced pancreatic cancer: current therapeutic approach. 2006
The promise of the human papillomavirus vaccine does not confer immunity against ethical reflection. 2006
Antibody-based therapies for colorectal cancer. 2005
Fertility-sparing options for patients with gynecologic malignancies. 2005
Targeted therapies for esophageal cancer. 2005
HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. 2005
Breast cancer in African-American women. 2005
Complementary and alternative therapies for cancer. 2004
An update on hepatic arterial infusion chemotherapy for colorectal cancer. 2003
Molecular genetics of neuroblastoma and the implications for clinical management: a review of the MSKCC experience. 2001
Thymoma: update for the new millennium. 2001
Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents. 2020
Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. 2019
Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. 2017
Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. 2015
Malignant peripheral nerve sheath tumors. 2014
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. 2011
Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. 2007
The role of mitoxantrone in the treatment of indolent lymphomas. 2005
Update on the management of inflammatory breast cancer. 2003
The mammography controversy. 2002
Sarcoma. 2001

VIVO Weill Cornell Medical College

The oncologist Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)